ArticleCancers2025
Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Breast-Conserving Surgery Versus Mastectomy After Neoadjuvant Therapy: A Survival Analysis.Annals of surgical oncology · 2026Article
- HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Oncological Outcomes of Breast-Conserving Surgery Versus Mastectomy in Invasive Lobular Breast Cancer: A Single-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Observational
- BrCaM an artificial intelligence model for surgical decision making in breast cancer.Scientific reports · 2026Article
- Oncologic safety of breast-conserving surgery in node-positive breast cancer: a systematic review and meta-analysis.Gland surgery · 2026Article
- Survival comparison of breast conserving therapy and mastectomy with breast reconstruction for breast cancer using propensity score matched cohort.Scientific reports · 2025Article
- Article
- Article
- Predictors of High-Burden Residual Axillary Disease After Neoadjuvant Therapy in Breast Cancer.Cancers · 2025Article
- Complete Pathological Response to Neoadjuvant Cisplatin, Etoposide, and Pembrolizumab in Small Cell Breast Carcinoma: A Case Report and Review of the Literature.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsNeoadjuvant therapy (NAT) is a cornerstone in the management of breast cancer (BC), enabling tumor downstaging and improved surgical options.
methodsThis study retrospectively analyzed 607 BC patients treated with NAT and surgery at IRCCS Humanitas Research Hospital, Milan, Italy, to compare long-term oncologic outcomes of breast-conserving surgery (BCS) versus mastectomy. Patient demographics, tumor characteristics, and treatment details were analyzed using descriptive statistics, logistic regression, and Cox proportional hazards models.
resultsOf the 607 patients, 54.7% underwent BCS, and 45.3% had mastectomy. BCS was associated with significantly superior 10-year outcomes compared to mastectomy, including disease-free survival (DFS, 75.2% vs. 71.1%,
conclusionsOur findings demonstrate the oncologic safety and potential superiority of BCS over mastectomy in NAT-treated BC patients, highlighting the importance of individualized surgical decision-making to optimize survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.